Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in Oklahoma
10 open options
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 159 sites
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
KarXT · Placebo — 129 sites
- TRIALNARECRUITING
Using Light Therapy for Mild Cognitive Impairment
Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation · Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation — 1 site
- TRIALPHASE2RECRUITING
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
BMS-986368 · Placebo — 75 sites
- TRIALPHASE2RECRUITING
Open-label Extension Study in Participants With Early Alzheimer's Disease
GSK4527226 — 33 sites
- TRIALPHASE2RECRUITING
tDCS for Post-Stroke Cognitive Impairment
Transcranial Dirrect Current Stimulation — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
KarXT · Placebo — 292 sites
- TRIALPHASE3RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
KarXT — 429 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
KarXT · KarX-EC — 256 sites
- TRIALPHASE2RECRUITING
Clinical Trial on Agitation in Alzheimer's Dementia
IGC-AD1-Active · IGC-AD1-Placebo — 31 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.